I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

FLORetina 2024

-
12:24 PM
Duration 3mins Session: San Frediano - Free Papers - Highlighted New Drugs DME
Faricimab▼ in DME: Results From the RHONE-X Long-Term Extension Trial
Pearce I, Abreu F, Gibson K, Khanani A, Kotak A, Lai TYY, Schlottmann P, Sim D, Tang Y, Kotecha A
12:27 PM
Duration 3mins Session: San Frediano - Free Papers - Highlighted New Drugs DME
Global Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Treatment-Nave Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema From a Multi-Country Prospective Non-Interventional Study: The VOYAGER Study
Parravano M, Bailey C, Chaikitmongkol V, Chaudhary V, Chi G, Downey A, Finger R, Gallego-Pinazo R, Koh A, Ishida S, L vestam-Adrian M, Pinto J, Schmitz-Valckenberg S, Sheth V, Shi B, Souied E, Uschner D, Guymer R
12:30 PM
Duration 3mins Session: San Frediano - Free Papers - Highlighted New Drugs DME
Indirect Comparison of the Relative Effectiveness of Faricimab▼ vs Aflibercept 8 mg in Diabetic Macular Edema (DME) and Neovascular Age-Related Macular Degeneration (nAMD)
Lupidi M, Keane P, Holekamp N, Leng T, Siedlecki J, Mar F, Gibson K, Margaron P, Paulo T, Buehrer C, Tabano D
12:36 PM
Duration 3mins Session: FREE PAPERS - HIGHLIGHTED NEW DRUGS DME
Port Delivery System With Ranibizumab for Continuous Treatment of Diabetic Macular Edema: First Readout of the Phase 3 Pagoda Trial Year 2 Results
Kitchens J, Awh C, Chang M, Rabena M, Wetzel-Smith M
01:06 PM
Duration 3mins Session: San Frediano - Free Papers - Highlighted New Drugs AMD 1
Treatment Patterns, Visual Outcomes and Safety in Eyes With neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) Treated With Faricimab▼ in the UK: 1-Year Results From the Faricimab▼ Real-World Evidence (FARWIDE) study
Pearce I, Talks J, De Salvo G, Patel JP, De Silva SR, Gale ERP, McKibbin M, Varma D, Peto T, Sivaprasad S, Reynolds R, Bailey C, Downey L, Kiire C, Chi GC, Ddodds M, James N, Downey A, Dayal P
01:09 PM
Duration 3mins Session: San Frediano - Free Papers - Highlighted New Drugs AMD 1
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
Cheung G, Chen SJ, Iida T, Koh A, Lee WK, Ruamviboonsuk P, Sun X, Yanagi Y, Bai R, Margaron P, Nguyen Duc A, Lai TYY
01:12 PM
Duration 3mins Session: San Frediano - Free Papers - Highlighted New Drugs AMD 1
Robust Vision Gains and Anatomical Improvement With Extended Faricimab▼ Dosing and Potential Q20W Dosing in Treatment-naïve Patients With nAMD in TENAYA/LUCERNE
Dhoot D, Ambresin A, Koh A, Patel P, Singer M, Dagincourt N, Hill L, Kotecha A, Margaron P
01:15 PM
Duration 3mins Session: SAN FREDIANO - FREE PAPERS - HIGHLIGHTED NEW DRUGS AMD 1
Reduction in Pigment Epithelial Detachments With Faricimab▼ vs Aflibercept in Patients With Treatment-Naïve nAMD: A TENAYA/LUCERNE Post Hoc Analysis
Lanzetta P, Ambresin A, Avery R, Chaikitmongkol V, Eter N, Gomi F, Khanani A, Lai TYY, Lim J, London N, Harrell E, Margaron P, Patel S, Souverain A, Yang M
01:30 PM
Duration 3mins Session: FREE PAPERS - HIGHLIGHTED NEW DRUGS AMD 1
Clinical Impact of the Port Delivery System With Ranibizumab (PDS) on Fibrosis in Patients With Neovascular Age-Related Macular Degeneration (nAMD) in the Phase 3 Archway trial
Heinrich D, Holekamp NM, Blotner S, Armendariz BG,Chakravarthy U
09:23 AM
Duration 4mins Session: SAN GIOVANNI - DIABETIC MACULAR EDEMA: TREATMENT 2
Real-World Effectiveness of Faricimab▼ in Patients: 12-Months Outcomes from the FARETINA Study
Leng T, Tabano D, Singh R, Ko S, Borkar D, Ali F
10:18 AM
Duration 3mins Session: ORSANMICHELE - FREE PAPERS - MYOPIA
Study Design and Rationale of POYANG: A Phase 3 Randomised Trial of Faricimab▼ for Choroidal Neovascularisation Secondary to Pathologic Myopia
Ruiz Moreno JM, Mehta H, Cheung G, Kotecha A, Lai T, O'Leary O, Rafijah N, Shah N, Willis J, Patel S, Lui W
Coming soon